In vitro Models of a Three-Drug Regimen (Epirubicin, Cisplatin and Fluorouracil) for the Treatment of Colorectal Cancer
The activity of epirubicin, cisplatin and 5-fluorouracil (5-FU), as single agents or in combination (ECF), was investigated in three human colon cancer cell lines by two different assays (cell-counting assay and sulforhodamine B assay) in vitro. 5-FU was tested with both short and continuous exposur...
Gespeichert in:
| Veröffentlicht in: | Chemotherapy (Basel) 2001-12, Vol.47 (6), p.430-437 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 437 |
|---|---|
| container_issue | 6 |
| container_start_page | 430 |
| container_title | Chemotherapy (Basel) |
| container_volume | 47 |
| creator | Caliò, Elisabetta Seminara, Patrizia Aronne, Teresa Sbaffi, Enrico Pagani Guazzugli Bonaiuti, Valerio Gargano, Letizia Franchi, Fabrizio |
| description | The activity of epirubicin, cisplatin and 5-fluorouracil (5-FU), as single agents or in combination (ECF), was investigated in three human colon cancer cell lines by two different assays (cell-counting assay and sulforhodamine B assay) in vitro. 5-FU was tested with both short and continuous exposure. Particular interest was focused on the results obtained in the HCT8-FU cell line, a subline with experimentally induced resistance to 5-FU. The positive modulation of both cisplatin and epirubicin cytotoxicity by 5-FU makes the ECF regimen an attractive protocol for combination therapy in colorectal cancer. |
| doi_str_mv | 10.1159/000048554 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_karger_primary_48554</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>677084491</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-d2b9e0e1332be8bf092a6ef7815882c2d0b284aedeef0f969b5a943eea400e993</originalsourceid><addsrcrecordid>eNptkM1r3DAQxUVpaTZpDz0XiggUEqhTfVi2dCzu5gNSCmF7NrI92ij1Ws7Ibsl_X212k1w6FzGjn94bPUI-cHbGuTJfWapcK5W_IgueC56Z0uSvySKNTSa5Kg_IYYx3qZWF5G_JAeelLgqlF-Tv1UD_-AkD_RE66CMNjlq6ukWA7DvOa3oDa7-BgZ4sR49z41s_fKGVj2NvJz9QO3T0vJ8Dhhlt6_tT6gLS6RboCsFO6eW0laxCHxDayfa0skML-I68cbaP8H5_HpFf58tVdZld_7y4qr5dZ63Uaso60RhgwKUUDejGMSNsAa7UXGktWtGxRujcQgfgmDOFaZQ1uQSwOWNgjDwixzvdEcP9DHGq79KmQ7KshZCi5KVkCTrdQS2GGBFcPaLfWHyoOau3CdfPCSf2015wbjbQvZD7SBPweQ_Y2NreYfqvjy-czBXjbGv6ccf9trgGfAaebI7_e1tdLh-Beuyc_AfnMZbQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223271730</pqid></control><display><type>article</type><title>In vitro Models of a Three-Drug Regimen (Epirubicin, Cisplatin and Fluorouracil) for the Treatment of Colorectal Cancer</title><source>Karger电子期刊和电子书数据库</source><source>MEDLINE</source><creator>Caliò, Elisabetta ; Seminara, Patrizia ; Aronne, Teresa ; Sbaffi, Enrico ; Pagani Guazzugli Bonaiuti, Valerio ; Gargano, Letizia ; Franchi, Fabrizio</creator><creatorcontrib>Caliò, Elisabetta ; Seminara, Patrizia ; Aronne, Teresa ; Sbaffi, Enrico ; Pagani Guazzugli Bonaiuti, Valerio ; Gargano, Letizia ; Franchi, Fabrizio</creatorcontrib><description>The activity of epirubicin, cisplatin and 5-fluorouracil (5-FU), as single agents or in combination (ECF), was investigated in three human colon cancer cell lines by two different assays (cell-counting assay and sulforhodamine B assay) in vitro. 5-FU was tested with both short and continuous exposure. Particular interest was focused on the results obtained in the HCT8-FU cell line, a subline with experimentally induced resistance to 5-FU. The positive modulation of both cisplatin and epirubicin cytotoxicity by 5-FU makes the ECF regimen an attractive protocol for combination therapy in colorectal cancer.</description><identifier>ISSN: 0009-3157</identifier><identifier>EISSN: 1421-9794</identifier><identifier>DOI: 10.1159/000048554</identifier><identifier>PMID: 11786658</identifier><identifier>CODEN: CHTHBK</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Adenocarcinoma - pathology ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Cell Count ; Chemotherapy ; Cisplatin - administration & dosage ; Cisplatin - adverse effects ; Colonic Neoplasms - pathology ; Drug Interactions ; Drug Resistance, Neoplasm ; Epirubicin - administration & dosage ; Epirubicin - adverse effects ; Experimental Chemotherapy ; Fluorescent Dyes ; Fluorouracil - administration & dosage ; Fluorouracil - adverse effects ; Humans ; Medical sciences ; Pharmacology. Drug treatments ; Rhodamines ; Tumor Cells, Cultured</subject><ispartof>Chemotherapy (Basel), 2001-12, Vol.47 (6), p.430-437</ispartof><rights>2001 S. Karger AG, Basel</rights><rights>2002 INIST-CNRS</rights><rights>Copyright 2001 S. Karger AG, Basel</rights><rights>Copyright (c) 2001 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c385t-d2b9e0e1332be8bf092a6ef7815882c2d0b284aedeef0f969b5a943eea400e993</citedby><cites>FETCH-LOGICAL-c385t-d2b9e0e1332be8bf092a6ef7815882c2d0b284aedeef0f969b5a943eea400e993</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13450100$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11786658$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Caliò, Elisabetta</creatorcontrib><creatorcontrib>Seminara, Patrizia</creatorcontrib><creatorcontrib>Aronne, Teresa</creatorcontrib><creatorcontrib>Sbaffi, Enrico</creatorcontrib><creatorcontrib>Pagani Guazzugli Bonaiuti, Valerio</creatorcontrib><creatorcontrib>Gargano, Letizia</creatorcontrib><creatorcontrib>Franchi, Fabrizio</creatorcontrib><title>In vitro Models of a Three-Drug Regimen (Epirubicin, Cisplatin and Fluorouracil) for the Treatment of Colorectal Cancer</title><title>Chemotherapy (Basel)</title><addtitle>Chemotherapy</addtitle><description>The activity of epirubicin, cisplatin and 5-fluorouracil (5-FU), as single agents or in combination (ECF), was investigated in three human colon cancer cell lines by two different assays (cell-counting assay and sulforhodamine B assay) in vitro. 5-FU was tested with both short and continuous exposure. Particular interest was focused on the results obtained in the HCT8-FU cell line, a subline with experimentally induced resistance to 5-FU. The positive modulation of both cisplatin and epirubicin cytotoxicity by 5-FU makes the ECF regimen an attractive protocol for combination therapy in colorectal cancer.</description><subject>Adenocarcinoma - pathology</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cell Count</subject><subject>Chemotherapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - adverse effects</subject><subject>Colonic Neoplasms - pathology</subject><subject>Drug Interactions</subject><subject>Drug Resistance, Neoplasm</subject><subject>Epirubicin - administration & dosage</subject><subject>Epirubicin - adverse effects</subject><subject>Experimental Chemotherapy</subject><subject>Fluorescent Dyes</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - adverse effects</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Rhodamines</subject><subject>Tumor Cells, Cultured</subject><issn>0009-3157</issn><issn>1421-9794</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkM1r3DAQxUVpaTZpDz0XiggUEqhTfVi2dCzu5gNSCmF7NrI92ij1Ws7Ibsl_X212k1w6FzGjn94bPUI-cHbGuTJfWapcK5W_IgueC56Z0uSvySKNTSa5Kg_IYYx3qZWF5G_JAeelLgqlF-Tv1UD_-AkD_RE66CMNjlq6ukWA7DvOa3oDa7-BgZ4sR49z41s_fKGVj2NvJz9QO3T0vJ8Dhhlt6_tT6gLS6RboCsFO6eW0laxCHxDayfa0skML-I68cbaP8H5_HpFf58tVdZld_7y4qr5dZ63Uaso60RhgwKUUDejGMSNsAa7UXGktWtGxRujcQgfgmDOFaZQ1uQSwOWNgjDwixzvdEcP9DHGq79KmQ7KshZCi5KVkCTrdQS2GGBFcPaLfWHyoOau3CdfPCSf2015wbjbQvZD7SBPweQ_Y2NreYfqvjy-czBXjbGv6ccf9trgGfAaebI7_e1tdLh-Beuyc_AfnMZbQ</recordid><startdate>20011201</startdate><enddate>20011201</enddate><creator>Caliò, Elisabetta</creator><creator>Seminara, Patrizia</creator><creator>Aronne, Teresa</creator><creator>Sbaffi, Enrico</creator><creator>Pagani Guazzugli Bonaiuti, Valerio</creator><creator>Gargano, Letizia</creator><creator>Franchi, Fabrizio</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20011201</creationdate><title>In vitro Models of a Three-Drug Regimen (Epirubicin, Cisplatin and Fluorouracil) for the Treatment of Colorectal Cancer</title><author>Caliò, Elisabetta ; Seminara, Patrizia ; Aronne, Teresa ; Sbaffi, Enrico ; Pagani Guazzugli Bonaiuti, Valerio ; Gargano, Letizia ; Franchi, Fabrizio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-d2b9e0e1332be8bf092a6ef7815882c2d0b284aedeef0f969b5a943eea400e993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adenocarcinoma - pathology</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cell Count</topic><topic>Chemotherapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - adverse effects</topic><topic>Colonic Neoplasms - pathology</topic><topic>Drug Interactions</topic><topic>Drug Resistance, Neoplasm</topic><topic>Epirubicin - administration & dosage</topic><topic>Epirubicin - adverse effects</topic><topic>Experimental Chemotherapy</topic><topic>Fluorescent Dyes</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - adverse effects</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Rhodamines</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Caliò, Elisabetta</creatorcontrib><creatorcontrib>Seminara, Patrizia</creatorcontrib><creatorcontrib>Aronne, Teresa</creatorcontrib><creatorcontrib>Sbaffi, Enrico</creatorcontrib><creatorcontrib>Pagani Guazzugli Bonaiuti, Valerio</creatorcontrib><creatorcontrib>Gargano, Letizia</creatorcontrib><creatorcontrib>Franchi, Fabrizio</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Chemotherapy (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Caliò, Elisabetta</au><au>Seminara, Patrizia</au><au>Aronne, Teresa</au><au>Sbaffi, Enrico</au><au>Pagani Guazzugli Bonaiuti, Valerio</au><au>Gargano, Letizia</au><au>Franchi, Fabrizio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro Models of a Three-Drug Regimen (Epirubicin, Cisplatin and Fluorouracil) for the Treatment of Colorectal Cancer</atitle><jtitle>Chemotherapy (Basel)</jtitle><addtitle>Chemotherapy</addtitle><date>2001-12-01</date><risdate>2001</risdate><volume>47</volume><issue>6</issue><spage>430</spage><epage>437</epage><pages>430-437</pages><issn>0009-3157</issn><eissn>1421-9794</eissn><coden>CHTHBK</coden><abstract>The activity of epirubicin, cisplatin and 5-fluorouracil (5-FU), as single agents or in combination (ECF), was investigated in three human colon cancer cell lines by two different assays (cell-counting assay and sulforhodamine B assay) in vitro. 5-FU was tested with both short and continuous exposure. Particular interest was focused on the results obtained in the HCT8-FU cell line, a subline with experimentally induced resistance to 5-FU. The positive modulation of both cisplatin and epirubicin cytotoxicity by 5-FU makes the ECF regimen an attractive protocol for combination therapy in colorectal cancer.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>11786658</pmid><doi>10.1159/000048554</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-3157 |
| ispartof | Chemotherapy (Basel), 2001-12, Vol.47 (6), p.430-437 |
| issn | 0009-3157 1421-9794 |
| language | eng |
| recordid | cdi_karger_primary_48554 |
| source | Karger电子期刊和电子书数据库; MEDLINE |
| subjects | Adenocarcinoma - pathology Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Cell Count Chemotherapy Cisplatin - administration & dosage Cisplatin - adverse effects Colonic Neoplasms - pathology Drug Interactions Drug Resistance, Neoplasm Epirubicin - administration & dosage Epirubicin - adverse effects Experimental Chemotherapy Fluorescent Dyes Fluorouracil - administration & dosage Fluorouracil - adverse effects Humans Medical sciences Pharmacology. Drug treatments Rhodamines Tumor Cells, Cultured |
| title | In vitro Models of a Three-Drug Regimen (Epirubicin, Cisplatin and Fluorouracil) for the Treatment of Colorectal Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T06%3A42%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20Models%20of%20a%20Three-Drug%20Regimen%20(Epirubicin,%20Cisplatin%20and%20Fluorouracil)%20for%20the%20Treatment%20of%20Colorectal%20Cancer&rft.jtitle=Chemotherapy%20(Basel)&rft.au=Cali%C3%B2,%20Elisabetta&rft.date=2001-12-01&rft.volume=47&rft.issue=6&rft.spage=430&rft.epage=437&rft.pages=430-437&rft.issn=0009-3157&rft.eissn=1421-9794&rft.coden=CHTHBK&rft_id=info:doi/10.1159/000048554&rft_dat=%3Cproquest_karge%3E677084491%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223271730&rft_id=info:pmid/11786658&rfr_iscdi=true |